CRSP heads into its May 11 earnings report carrying one of the most crowded short positions in biotech — and fresh evidence that options traders turned meaningfully more defensive this week.
The options signal is the sharpest development. The put/call ratio jumped to 0.64 on Tuesday, more than 2.5 standard deviations above its 20-day average of 0.55. That is the highest reading of the past year. In plain terms, traders have rarely loaded up on downside protection at this level relative to calls — pointing to an unusual degree of caution heading into the report. The timing is precise: the PCR had been broadly stable since late March, making the spike over the last two sessions stand out sharply.
Short interest has been running hot all year, but the direction is notably shifting. At 22.5% of free float, the short position is substantial by any measure — ranking in the top 2% of the universe by short score percentile, with an ORTEX short score of 81.9. Yet shorts have quietly trimmed over the past week, falling nearly 6% in that span, extending a pullback that started in mid-April when the position peaked above 24%. That unwinding has not crushed the absolute level, but it does mean shorts are reducing exposure into the catalyst rather than pressing it. Borrow availability remains quite tight — the lending pool is roughly 86% utilised — but cost to borrow has eased back to sub-1% after briefly spiking to 3.4% on April 16. The combination of retreating shorts and falling borrow cost suggests the squeeze risk that briefly looked acute a few weeks ago has cooled somewhat.
The Street is broadly constructive but not uniform. Most recent analyst moves have been target raises. This week, Citigroup lifted its target to $82 while maintaining Buy. Piper Sandler reiterated Overweight in March with a $110 target — the most bullish on the board. The lone holdout is TD Cowen at Hold with a $45 target, well below the $82 mean target consensus. That consensus implies roughly 57% upside to the current $52.38 price. The bull case centres on Casgevy's launch potential in sickle-cell disease and beta thalassemia, plus an expanding CAR-T pipeline for autoimmune conditions. Bears counter with a difficult commercialisation path — Casgevy's high price and logistical complexity are real barriers — and a net income loss running near $486 million annually on just $56 million of estimated revenue. The price-to-book multiple of 3.5x has climbed around 9% over the past month, narrowing the margin of safety for value-conscious holders.
Institutional positioning adds an interesting layer. ARK Investment Management remains the largest disclosed holder with 11.3 million shares, or nearly 12% of the company, and added 791,566 shares through April 30. BlackRock added 458,000 shares in the same period. GSK Equity Investments reported a position of 3.2 million shares that appears to be a new holding entirely. The insider register offers little comfort: the CEO, CFO, CMO, and General Counsel all sold stock in mid- to late March at prices around $47–$48, netting a combined $1.7 million in proceeds across those sessions. These were modest-sized sales relative to company shares outstanding, and the significance ratings were low — likely part of pre-set 10b5-1 plans — but the direction was uniformly one way.
Looking at prior earnings reactions, CRSP has posted broadly positive responses to recent results: a 9.8% jump the next day in February, then a 2.8% gain in the subsequent print. The May 4 announcement moved just 1.5%. The track record is not one-directional, however — November 2025 produced a 4.4% decline. The upcoming May 11 report is the next data point in that sequence, with the PCR spike and the elevated short position — even if shrinking — together framing a market that is more hedged than usual into the catalyst.
See the live data behind this article on ORTEX.
Open CRSP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
